Zolbend 400 Chewable Tablet 1

Some of the essential drug-drug interactions of Zolbend 400 Chewable Tablet 1 include:

• Anthelmintic: When taken simultaneously with praziquantel, an anthelmintic drug, there is an increased risk of liver toxicity. Therefore, the simultaneous use of these drugs should be avoided or monitored closely.
• Corticosteroid: The simultaneous use of corticosteroids, such as dexamethasone and albendazole, may increase the risk of central nervous system toxicity, like seizures. Therefore, the use of these drugs together should be avoided, or their use should be monitored closely.
• Antacid: Simultaneous use of cimetidine, an antacid, with albendazole may reduce albendazole absorptione. Therefore, it is recommended to separate the administration of these drugs by at least two hours.
• Anti-asthma: The simultaneous use of theophylline, an anti-asthma drug, and albendazole may increase the serum levels of theophylline, leading to toxicity. Therefore, the use of these drugs together should be avoided, or their use should be monitored closely.

Here are the drug-disease interactions to consider:

• Myelosuppression: Zolbend 400 Chewable Tablet 1 may cause bone marrow suppression, leading to decreased blood cell production. Regular monitoring of blood counts is recommended. Patients with a history of blood disorders, such as anaemia, leukopenia, or thrombocytopenia, should use the Zolbend 400 Chewable Tablet 1 cautiously.
• Hepatobiliary dysfunction: Patients with liver and biliary diseases should use Zolbend 400 Chewable Tablet 1 cautiously as it may worsen their condition. Zolbend 400 Chewable Tablet 1 is metabolised in the liver, and its use may raise the possibility of liver damage or liver function abnormalities. Patients with liver diseases, such as hepatitis or cirrhosis, should be monitored closely while taking Zolbend 400 Chewable Tablet 1.
• Neurological disorder: Zolbend 400 Chewable Tablet 1 may cause neurological side effects like headache, dizziness, and seizures. Close monitoring is recommended to ensure that any neurological symptoms are promptly identified and treated. Patients with a history of neurological disorders, such as epilepsy or seizures, should use Zolbend 400 Chewable Tablet 1 carefully.
• Kidney dysfunction: Zolbend 400 Chewable Tablet 1 is eliminated from the body through the kidneys. Patients with kidney dysfunction or renal impairment may have a slower drug elimination, leading to an increased risk of adverse effects. While taking Zolbend 400 Chewable Tablet 1, patients with kidney disorders should be closely observed.

The recommended dose of Zolbend 400 Chewable Tablet 1 is once daily, with food, as directed by your doctor. The dosage may change based on individual factors such as the severity of the condition and response to treatment. It is crucial to follow the suggested dosage and not exceed it without consulting your doctor. 

If you or someone else takes an excessive amount of Zolbend 400 Chewable Tablet 1 by accident, it is essential to take immediate medical attention from your doctor or nearby hospital. Symptoms of an overdose include diarrhoea, vomiting, and rapid heartbeats.

If you forgot to take a Zolbend 400 Chewable Tablet 1, take it as early as you recall. If the time for the next dosage is close, skipping the missed one is recommended and resume your regular dosage pattern. Avoid consuming extra doses without consulting your doctor.